Tags

Type your tag names separated by a space and hit enter

Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia.
Bone Marrow Transplant. 1999 Jun; 23(11):1095-100.BM

Abstract

This is a prospective study designed to determine the toxicity, efficacy and antileukemic effect of high-dose cytosine arabinoside (ara-C), cyclophosphamide and total body irradiation (TBI) as a myeloablative regimen prior to allogeneic bone marrow transplantation for patients with hematologic malignancies. Fifty-eight patients with hematologic malignancies were treated with cyclophosphamide, high-dose ara-C and total body irradiation (TBI) followed by allogeneic bone marrow transplantation. Fifty patients had good prognosis disease and eight had poor prognosis disease. Cyclosporine and short-course methotrexate were used for graft-versus-host disease (GVHD) prophylaxis. The conditioning regimen consisted of ara-C 3000 mg/m2 twice a day x six doses on days -7, -6, and -5; cyclophosphamide 1800 mg/m2 on days -4 and -3; and TBI 1400 cGy midline dose at 5 cGy/min in eight total fractions administered twice a day on days -4, -3, -2, and -1. The bone marrow was infused on day 0 (zero). Toxicity related to the conditioning regimen was comparable to that reported with other conditioning regimens, except for diarrhea which appears to be more frequent. The actuarial survival at 1 year was 69% (58-82) and at 5 years was 54% (42-69) with the numbers in parentheses representing the 95% confidence interval of the Kaplan-Meier estimate. After a median follow-up of 28 months, 31 of 58 (53%) patients are alive without evidence of disease. Only four of the 58 patients (7%) have relapsed. Cyclophosphamide, ara-C and TBI is a safe and effective myeloablative regimen for patients with leukemia. The overall relapse rate in our study was 7% with a median follow-up of 28 months and appears to be lower than relapse rates reported in other series. This is probably due to the added antileukemic effect of ara-C. This regimen should be compared with other myeloablative regimens in a controlled study.

Authors+Show Affiliations

Department of Medicine, Yale University School of Medicine and Yale Comprehensive Cancer Center, New Haven, CT, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

10382947

Citation

Jillella, A P., et al. "Cyclophosphamide, Cytosine Arabinoside and TBI as a Conditioning Regimen for Allogeneic Bone Marrow Transplantation in Patients With Leukemia." Bone Marrow Transplantation, vol. 23, no. 11, 1999, pp. 1095-100.
Jillella AP, Doria R, Khan K, et al. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia. Bone Marrow Transplant. 1999;23(11):1095-100.
Jillella, A. P., Doria, R., Khan, K., Zelterman, D., Ahmad, Y. H., Smith, B. R., Holmes, W., Becker, P., Roberts, K. B., & Rappeport, J. M. (1999). Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia. Bone Marrow Transplantation, 23(11), 1095-100.
Jillella AP, et al. Cyclophosphamide, Cytosine Arabinoside and TBI as a Conditioning Regimen for Allogeneic Bone Marrow Transplantation in Patients With Leukemia. Bone Marrow Transplant. 1999;23(11):1095-100. PubMed PMID: 10382947.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia. AU - Jillella,A P, AU - Doria,R, AU - Khan,K, AU - Zelterman,D, AU - Ahmad,Y H, AU - Smith,B R, AU - Holmes,W, AU - Becker,P, AU - Roberts,K B, AU - Rappeport,J M, PY - 1999/6/26/pubmed PY - 1999/6/26/medline PY - 1999/6/26/entrez SP - 1095 EP - 100 JF - Bone marrow transplantation JO - Bone Marrow Transplant VL - 23 IS - 11 N2 - This is a prospective study designed to determine the toxicity, efficacy and antileukemic effect of high-dose cytosine arabinoside (ara-C), cyclophosphamide and total body irradiation (TBI) as a myeloablative regimen prior to allogeneic bone marrow transplantation for patients with hematologic malignancies. Fifty-eight patients with hematologic malignancies were treated with cyclophosphamide, high-dose ara-C and total body irradiation (TBI) followed by allogeneic bone marrow transplantation. Fifty patients had good prognosis disease and eight had poor prognosis disease. Cyclosporine and short-course methotrexate were used for graft-versus-host disease (GVHD) prophylaxis. The conditioning regimen consisted of ara-C 3000 mg/m2 twice a day x six doses on days -7, -6, and -5; cyclophosphamide 1800 mg/m2 on days -4 and -3; and TBI 1400 cGy midline dose at 5 cGy/min in eight total fractions administered twice a day on days -4, -3, -2, and -1. The bone marrow was infused on day 0 (zero). Toxicity related to the conditioning regimen was comparable to that reported with other conditioning regimens, except for diarrhea which appears to be more frequent. The actuarial survival at 1 year was 69% (58-82) and at 5 years was 54% (42-69) with the numbers in parentheses representing the 95% confidence interval of the Kaplan-Meier estimate. After a median follow-up of 28 months, 31 of 58 (53%) patients are alive without evidence of disease. Only four of the 58 patients (7%) have relapsed. Cyclophosphamide, ara-C and TBI is a safe and effective myeloablative regimen for patients with leukemia. The overall relapse rate in our study was 7% with a median follow-up of 28 months and appears to be lower than relapse rates reported in other series. This is probably due to the added antileukemic effect of ara-C. This regimen should be compared with other myeloablative regimens in a controlled study. SN - 0268-3369 UR - https://www.unboundmedicine.com/medline/citation/10382947/Cyclophosphamide_cytosine_arabinoside_and_TBI_as_a_conditioning_regimen_for_allogeneic_bone_marrow_transplantation_in_patients_with_leukemia_ L2 - https://doi.org/10.1038/sj.bmt.1701786 DB - PRIME DP - Unbound Medicine ER -